Literature DB >> 1723767

Hypothyroidism renders protection against lethal ventricular arrhythmias in a conscious canine model of sudden death.

N Venkatesh1, J J Lynch, A C Uprichard, J M Kitzen, B N Singh, B R Lucchesi.   

Abstract

The protective effect of hypothyroidism against lethal ventricular tachyarrhythmias (VT) in the subacute phase of experimental myocardial infarction (MI) was investigated in 10 thyroidectomized dogs using a conscious model of sudden coronary death. Four weeks after surgical ablation of the thyroid, and having established biochemical hypothyroidism, anterior MI was produced by 120 min of occlusion-reperfusion of the left anterior descending coronary artery. In the subacute phase of MI, the inducibility of VT was investigated using programmed ventricular stimulation (PVS), and the effects on spontaneous development of ventricular fibrillation (VF) were studied by production of posterolateral ischemia at a site remote from the area of the previous infarction. Ischemia was produced by the passage of anodal direct current through a silver wire electrode implanted in the left circumflex coronary (LCX) artery. The results were compared to those from a cohort of 20 existing euthyroid controls that had undergone an identical experimental protocol. No differences were found in heart rate and other electrocardiographic parameters such as the PR, QRS, and QT (paced at 2.5 Hz) and the QTc interval between the hypo- and euthyroid groups. During PVS in the subacute phase of anterior MI, the measured threshold voltage and ventricular refractory periods were similar in both groups. The incidence of inducibility of VT was 100% in the euthyroid animals compared to 60% in the hypothyroid dogs, suggesting an antiarrhythmic effect of hypothyroidism. The incidence of sustained vs. nonsustained VT was similar in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723767     DOI: 10.1097/00005344-199111000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Hypothyroidism, thyroxine treatment, and the heart.

Authors:  M Gammage; J Franklyn
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

2.  Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: a comparative study with amiodarone.

Authors:  P Liu; L Fei; W Wu; J Li; J Wang; X Zhang
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

3.  The effects of L-thyroxine treatment on QT dispersion in primary hypothyroidism.

Authors:  Kyoung Hee Kweon; Byoung Hyun Park; Chung Gu Cho
Journal:  J Korean Med Sci       Date:  2007-02       Impact factor: 2.153

4.  Thyroid dysfunction and electrocardiographic changes in subjects without arrhythmias: a cross-sectional study of primary healthcare subjects from Copenhagen.

Authors:  Bhupendar Tayal; Claus Graff; Christian Selmer; Kristian Hay Kragholm; Magnus Kihlstrom; Jonas Bille Nielsen; Anne-Marie Schjerning Olsen; Adrian Holger Pietersen; Anders G Holst; Peter Søgaard; Christine Benn Christiansen; Jens Faber; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Steen M Hansen
Journal:  BMJ Open       Date:  2019-06-21       Impact factor: 2.692

Review 5.  The Role of Thyroid Diseases and their Medications in Cardiovascular Disorders: A Review of the Literature.

Authors:  Negar Omidi; Mohammadrafie Khorgami; Farbod Z Tajrishi; Amirhosein Seyedhoseinpour; Parichehr Pasbakhsh
Journal:  Curr Cardiol Rev       Date:  2020

6.  Thyroid hormones and electrocardiographic parameters: findings from the third national health and nutrition examination survey.

Authors:  Yiyi Zhang; Wendy S Post; Alan Cheng; Elena Blasco-Colmenares; Gordon F Tomaselli; Eliseo Guallar
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

Review 7.  New aspects of endocrine control of atrial fibrillation and possibilities for clinical translation.

Authors:  Martin Aguilar; Robert A Rose; Abhijit Takawale; Stanley Nattel; Svetlana Reilly
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.